Gilead Sciences Stock Dips 022% on $1076 Billion Trading Volume Ranking 71st in Market Activity

On April 24, 2025, Gilead Sciences (GILD) experienced a slight decline of 0.22% in its stock price, with a trading volume of $10.76 billion, ranking 71st in the day's market activity.

Gilead Sciences reported a strong first quarter of 2025, with net income of $1.32 billion, marking a return to profitability. The company's base business growth offset declines in Veclury, a COVID-19 treatment, due to lower hospitalization rates. Gilead maintained its full-year non-GAAP guidance, reflecting confidence in its financial outlook.

During the quarter, Gilead paid dividends of $1.0 billion and repurchased $730 million of common stock, demonstrating its commitment to returning value to shareholders. The company also repaid $1.8 billion in debt, further strengthening its financial position.

Gilead's HIV business continued to grow, with sales increasing by 6% year-over-year, driven by higher average realized prices and demand. Biktarvy, a key HIV treatment, saw a 7% increase in sales, maintaining its market leadership. The U.S. PrEP market also grew by 16% year-over-year, reflecting increased awareness and access.

In the liver disease segment, sales increased by 3% year-over-year, driven by increased demand for PBC, HBV, and HDV treatments. Livdelzi, a recently launched PBC treatment, showed strong early momentum, with sales of $40 million in the first quarter.

Gilead's oncology segment faced headwinds, with sales decreasing by 4% year-over-year. Yescarta, a cell therapy, saw a 2% increase in sales, while Tecartus faced increased competition, leading to a 22% decrease in sales. Trodelvy, another oncology treatment, experienced a 5% decrease in sales due to inventory dynamics and lower demand.

Looking ahead, Gilead expects to submit regulatory filings for lenacapavir, a long-acting HIV treatment, in multiple regions. The company also plans to initiate a Phase 3 trial for once-yearly lenacapavir for PrEP in the second half of 2025. Additionally, Gilead expects to launch up to nine new HIV products by the end of 2033.